Ashley Gallagher

Meloxicam and rizatriptan (Symbravo, formerly AXS-07) is a CGRP medication approved for the acute treatment of migraine with or without aura.

The updated label also includes alternative injection sites, such as the abdomen, thigh, buttock, or back of the upper arm.

The study authors report that long-term daily administration of amlodipine induced behavioral changes in the rats during their open field test.

Semaglutide has been in shortage since 2022 due to increased demand.

Measles is highly contagious, and the Texas Department of State Health Services said that additional cases are likely to occur in Gaines County, which had 57 cases as of February 21, 2025.

Tirzepatide (Mounjaro, Zepbound), a glucagon-like peptide-1 (GLP-1) medication, demonstrates improved diabetes control and decreases in insulin requirements.

By 12 weeks, investigators report that SkinTE facilitated significantly more wound closures compared with the standard of care.

Recently, the FDA alerted users of missed notifications for continuous glucose monitoring devices and Bluetooth smartphone compatibility.

The FDA also granted priority review, with a Prescription Drug User Fee Act target action date of August 19, 2025.

ASC30, an investigational glucagon-like 1-peptide receptor agonist, demonstrates mean weight reductions from baseline of 4.3% and 6.3% for 2 separate cohorts.

The FDA initially approved deucravacitinib (Sotyktu) in September 2022 to treat moderate-to-severe plaque psoriasis.

Previously, dupilumab (Dupixent) received orphan drug designation for bullous pemphigoid.

The vaccine is the first virus-like particle single-dose vaccine for chikungunya for patients 12 years and older.

Denosumab-dssb is approved as a 60 mg pre-filled syringe as a biosimilar for Prolia and 120 mg vial as a biosimilar for Xgeva.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

Currently, blood-thinning medications are only prescribed to patients who have already had a heart attack or stroke, as the drugs can cause serious bleeding.

The drug is the first rapid-acting insulin biosimilar product approved for use by the FDA, marking a significant milestone in diabetes treatment.

Identifying women who are at risk for postpartum depression sooner can lead to quicker and possibly preventative treatment.

Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.

A dose response is observed with the highest dose of the drug and mitigating withdrawal symptoms for patients with cannabis use disorder.

For weight loss and antihypertensive effects on systolic and diastolic blood pressure, semaglutide also had increased effects.

The tablet formation of risdiplam (Evrysdi) demonstrates bioequivalence to the oral formulation of the drug.

The designation is based on the AMULET phase 2 trial, which was the first-in-human study of the drug.

Data has shown the investigational cell therapy is well-tolerated in patients and showed preliminary impacts on cognition.

Recently, there has been concern around glucagon-like peptide-1 receptor agonists and increase the risk of thyroid cancer, with liraglutide having a black box warning label for the disease.

Social media can help close the gap on health care information access, but pharmacists still play a large role in diabetes management, especially in therapeutics.

Poor cardiometabolic health is associated with cognitive impairment in later life, but there is no clear association between cardiometabolic trajectories and early markers.

Expert highlights the benefits of using apomorphine infusion to provide more consistent medication levels and reduce the unpredictable fluctuations.

Data from a previous phase 1b trial show improvements in the Eczema Area and Severity Index (EASI)-75 compared with the placebo at 12 weeks.

Patients who achieved clinical remission at 1 year in VIVID-1 maintain clinical remission at 92.9% at 2 years with the Crohn Disease Activity Index.